Neglected and Tropical Diseases Required Information Indicator Definition

Primary Program Area (Program Element for IIP) Linkage Primary Program Element (Program Sub-Element for IIP) Linkage Linkage to LongTerm Outcome or Impact

Indicator Type Unit of Measure

Use of Indicator

Methodology for

Response Number of Neglected Tropical Disease (NTD) Treatments delivered through USG-funded programs. Treatments: age and height appropriate dosage of a NTD specific drug administered to an eligible person in a defined geographic area. Each drug dose is counted as a single treatment such that an individual may receive multiple treatments if treated for multiple diseases and with multiple drugs. The Neglected Tropical Diseases (NTD) targeted by the program are onchocerciasis, schistosomiasis, lymphatic filariasis, trachoma and soiltransmitted helminthes (whipworm, hookworm and roundworm.) Element: 3.1.5 - Other Public Health Threats

Sub-Element 3.1.5.1: Other Infectious Diseases

The preferred strategy to control and reduce the burden of targeted neglected tropical diseases is preventive chemotherapy (PCT) delivered through mass drug administration (MDA). PCT reduces the infection load and disease burden in individuals. Repeated MDA decreases disease prevalence in communities which leads to a reduction in transmission and thus in incidence. A reduced infection load and disease burden combined with a decrease in disease prevalence and incidence will result in the control and elimination of the targeted neglected tropical diseases as a public health problem. This indicator is for reporting by field OUs. This program is centrally funded and managed; the Global Health Bureau also collects and reports on higher-level indicators for the NTD program reflecting progress towards the GHI targets for NTDs. Output Number of treatments For definition of treatment see above. The number is specific to the year; a cumulative number can be calculated to provide the treatments delivered since the start of the program. This is a GHI indicator. The indicator is used for program planning, budgeting and reporting. In-country program managers and partners use the indicator for program performance review, drug supply management (including forecasting and ordering drugs from donors and other suppliers) and budgeting. The number of treatments is calculated annually for each USAID-

Aggregation What countries are included in the aggregate data point – please note changes over time

Is this data reflective of USG funding only? Data Source

Reporting Frequency

supported country, and summed annually across USAID’s NTD Program. FY08

FY09

FY10

FY11 FY13 FY15 projections projections projections

Burkina Faso Ghana Haiti Mali Niger Sierra Leone Uganda

Burkina Faso Cameroon Ghana Haiti Mali Niger Sierra Leone Southern Sudan Togo Uganda

Burkina Faso Cameroon Ghana Haiti Indonesia Mali Nepal Niger Sierra Leone Southern Sudan Tanzania Togo Uganda

Burkina Faso Cameroon Ghana Haiti Indonesia Mali Nepal Niger Sierra Leone Tanzania Togo Uganda

Burkina Faso Cameroon Ghana Haiti Indonesia Mali Mozambique Nepal Niger Senegal Sierra Leone Tanzania Togo Uganda

Burkina Faso Cameroon Ghana Haiti Indonesia Mali Mozambique Nepal Niger Senegal Sierra Leone Tanzania Togo Uganda

All reported treatments are administered with USAID support, although other partners may also contribute financial and/or technical support to the Ministries of Health to complement USAID-funded MDA. Semi Annual project reports. Data is gathered by drug distributors, who are most often community drug distributors or school teachers. Distributors are trained in drug distribution, record keeping and reporting. Data is then reported through the national reporting system. Most drugs are taken under direct observation by the distributors. Annual

Known Data Limitations

Standard, internationally accepted data collection and reporting tools are in place and in use. In most settings treatment (drug intake) is observed. As treatments (drugs) are distributed by thousands of community workers, sometimes under hectic circumstances, errors in recording may occur. To reduce errors, training and regular supervision is conducted by implementing partners in collaboration with national governments. Data are reviewed by implementing partners before reporting.

2008 Baseline Data & Comments 2009 Data & Comments 2010 Data & Comments 2011 Projection & Comments

130 Million

2013 Projection & Comments 2015 Projection & Comments

160 million 208 million 198 Million; slowed increase in treatment numbers due to achieving criteria for stopping MDA and therefore termination of successful programs 150 Million; slowed increase in treatment numbers due to achieving criteria for stopping MDA and therefore termination of successful programs 85 Million; slowed increase in treatment numbers due to achieving criteria for stopping MDA and therefore termination of successful 2

programs Responsibility

Disaggregate(s)

Required Information Indicator Definition

USAID/GH/HIDN/ID Emily Wainwright 202-712-5403 [email protected] Changes in global reporting forms will allow for numbers disaggregated by sex to become available. This is anticipated to begin in 2013.

Response Number of lymphatic filariasis endemic districts with prevalence of